[go: up one dir, main page]

MX2018014929A - Conjugados de un agente farmaceutico y una porcion capaz de unirse a una proteina sensora de glucosa. - Google Patents

Conjugados de un agente farmaceutico y una porcion capaz de unirse a una proteina sensora de glucosa.

Info

Publication number
MX2018014929A
MX2018014929A MX2018014929A MX2018014929A MX2018014929A MX 2018014929 A MX2018014929 A MX 2018014929A MX 2018014929 A MX2018014929 A MX 2018014929A MX 2018014929 A MX2018014929 A MX 2018014929A MX 2018014929 A MX2018014929 A MX 2018014929A
Authority
MX
Mexico
Prior art keywords
pharmaceutical agent
binding
conjugates
moiety capable
glucose sensing
Prior art date
Application number
MX2018014929A
Other languages
English (en)
Inventor
Petry Stefan
Werner Ulrich
Plettenburg Oliver
Tennagels Norbert
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2018014929A publication Critical patent/MX2018014929A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/10—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

La invención describe conjugados novedosos de formula (I) de un agente farmacéutico y una porción capaz de unirse a una proteína censora de glucosa que permite una liberación reversible del agente farmacéutico que depende de la concentración de glucosa.
MX2018014929A 2016-06-02 2017-06-02 Conjugados de un agente farmaceutico y una porcion capaz de unirse a una proteina sensora de glucosa. MX2018014929A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305640 2016-06-02
PCT/EP2017/063447 WO2017207754A1 (en) 2016-06-02 2017-06-02 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein

Publications (1)

Publication Number Publication Date
MX2018014929A true MX2018014929A (es) 2019-08-26

Family

ID=56121007

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014929A MX2018014929A (es) 2016-06-02 2017-06-02 Conjugados de un agente farmaceutico y una porcion capaz de unirse a una proteina sensora de glucosa.

Country Status (13)

Country Link
US (3) US11090364B2 (es)
EP (1) EP3463480A1 (es)
JP (1) JP2019520342A (es)
KR (1) KR20190015413A (es)
CN (1) CN109562185A (es)
AU (1) AU2017272862A1 (es)
BR (1) BR112018074716A2 (es)
CA (1) CA3025988A1 (es)
IL (1) IL263390A (es)
MX (1) MX2018014929A (es)
RU (1) RU2018147235A (es)
SG (1) SG11201810701XA (es)
WO (1) WO2017207754A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109562185A (zh) 2016-06-02 2019-04-02 赛诺菲 药剂与能够结合葡萄糖感应蛋白的部分的新颖缀合物
JP2021504402A (ja) 2017-12-01 2021-02-15 サノフイＳａｎｏｆｉ 薬剤とグルコース感知タンパク質に結合し得る部分との新規のコンジュゲート
AU2022215844A1 (en) 2021-02-02 2023-09-14 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
CN115920081B (zh) * 2022-11-02 2024-07-19 重庆大学 红细胞膜自发定向包被ros响应的纳米前药及其应用
WO2025199666A1 (en) * 2024-03-25 2025-10-02 Canwell Biotech Limited Multivalent linkers for high loading antibody-drug conjugates, and compositions and methods thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK111489D0 (da) 1989-03-08 1989-03-08 Novo Nordisk As Peptider
EP1290024A1 (en) 2000-06-02 2003-03-12 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
EP1453860A2 (en) 2001-12-02 2004-09-08 Novo Nordisk A/S Novel glucose-dependant insulins
CN102026666B (zh) * 2007-12-11 2013-10-16 常山凯捷健生物药物研发（河北）有限公司 促胰岛素肽缀合物制剂
FR2929615B1 (fr) 2008-04-02 2010-12-17 Tfchem Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.
CN101638423B (zh) 2008-07-29 2012-09-05 常州高新技术产业开发区三维工业技术研究所有限公司 根皮苷衍生物及其制备方法和用途
BRPI0919411A2 (pt) 2008-09-19 2015-12-15 Novartis Ag derivado de glicosídeo e usos dos mesmos
BRPI1007466A2 (pt) * 2009-01-28 2018-06-12 Smartcells Inc conjugado de insulina cristalina, formulação de liberação prolongada, e, sistema de distribuição de bomba
MX2011007929A (es) * 2009-01-28 2011-08-17 Smartcells Inc Sistemas basados en conjugados para entrega farmacologica controlada.
WO2010107520A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
WO2011000823A1 (en) 2009-06-30 2011-01-06 Novo Nordisk A/S Insulin derivatives
CA2794266C (en) * 2010-03-24 2020-09-08 Ohio University Compositions and methods for glucose transport inhibition
CA2806399A1 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
WO2012015681A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
BR112013026361A2 (pt) 2011-04-14 2016-12-27 Novartis Ag derivados de glicosídeo e usos dos mesmos
WO2012177701A2 (en) 2011-06-20 2012-12-27 Radiomedix Inc. Compositions, methods of synthesis and use of carbohydrate targeted agents
CN110075283A (zh) 2012-02-15 2019-08-02 洛桑聚合联合学院 红细胞结合性治疗剂
HK1204578A1 (en) 2012-03-21 2015-11-27 Erytech Pharma Medicament for the treatment of acute myeloid leukemia (aml)
WO2013182612A1 (en) * 2012-06-07 2013-12-12 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
EP2813234A1 (en) 2013-06-11 2014-12-17 Erytech Pharma Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof
WO2015051052A2 (en) 2013-10-04 2015-04-09 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
US10751425B2 (en) 2014-01-15 2020-08-25 Baseclick Gmbh Saccharide-modified nucleic acid molecules
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
WO2017124102A1 (en) 2016-01-14 2017-07-20 North Carolina State University Glucose responsive insulin delivery compositions and methods
CN109562185A (zh) * 2016-06-02 2019-04-02 赛诺菲 药剂与能够结合葡萄糖感应蛋白的部分的新颖缀合物

Also Published As

Publication number Publication date
KR20190015413A (ko) 2019-02-13
US11090364B2 (en) 2021-08-17
US20210401947A1 (en) 2021-12-30
US20190209656A1 (en) 2019-07-11
JP2019520342A (ja) 2019-07-18
CN109562185A (zh) 2019-04-02
EP3463480A1 (en) 2019-04-10
BR112018074716A2 (pt) 2019-03-12
AU2017272862A1 (en) 2019-01-17
RU2018147235A (ru) 2020-07-10
US20210401946A1 (en) 2021-12-30
WO2017207754A1 (en) 2017-12-07
SG11201810701XA (en) 2018-12-28
IL263390A (en) 2018-12-31
CA3025988A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
MA41265B1 (fr) Compositions pour administration de médicaments iléo-jéjunal.
EP3700416A4 (en) PRE-CONNECTED ANALYSIS SENSORS
IL269690B (en) Conjugates containing an anthracycline drug-binding protein and their uses
DK3576788T3 (da) Farmaceutisk sammensætning med lavt ph, der omfatter t-celle-engagerende antistofkontruktioner
DK3458102T3 (da) Anti-cmet-antistoflægemiddelkonjugater og fremgangsmåder til anvendelse deraf
PL3283521T3 (pl) Koniugaty leków zawierające przeciwciała przeciwko klaudynie 18.2
DK3478693T3 (da) Boronsyrederivater og terapeutiske anvendelser deraf
CL2014001930A1 (es) Formulacion farmacéutica que comprende un anticuerpo angiopoyetina 2 (anti-ang2).
DK3334500T3 (da) Multiligand-lægemiddelskonjugater og anvendelser deraf
MX2018014929A (es) Conjugados de un agente farmaceutico y una porcion capaz de unirse a una proteina sensora de glucosa.
BR112017028517A2 (pt) ?composição farmacêutica, vetor, peptídeo, polinucleotídeo e conjugado isolado e composição?
WO2015164392A8 (en) Novel anti-rnf43 antibodies and methods of use
DK3412660T3 (da) Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme
HUE046850T2 (hu) Új 2' és/vagy 5' aminosav észter foszforamidát 3'-deoxi adenozin származékok mint anti-rák vegyületek
HUE055231T2 (hu) Inzulint tartalmazó gyógyászati készítmények
IL273551A (en) Boronic acid derivatives and their synthesis
GB201608936D0 (en) Novel conjugates and novel conjugating reagents
JOP20170115B1 (ar) مشتقات بيريدينيل، تركيبات صيدلية منها واستخداماتها كمثبطات aoc3
MA53732A (fr) Anticorps dirigés contre bcma soluble
MA32321B1 (fr) Pregn-4-en-21, 17 carbolactones substitués sur le noyau c, et préparations pharmaceutiques contenant ces derniers
MX372607B (es) Sal de succinato de citisina y uso de la misma
EP3605103A4 (en) MARKER FOR DETERMINING SENSITIVITY TO A COMBINED ANTI-CANCER MEDICINE
BR112017005993A2 (pt) derivados de peptídeo inovadores e usos dos mesmos
EP3623384A4 (en) ANTI-CLDN-5 ANTIBODY AND ACTIVE SUBSTANCE WITH THIS ANTIBODY
CY1120192T1 (el) Ενωσεις για την ενισχυση της γνωστικης λειτουργιας